Search results
Results from the WOW.Com Content Network
September 27, 2024 at 9:39 AM. (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly ...
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
COVID-19 Antigen Rapid Test Kit; the timer is provided by the user. Mucus from nose or throat in a test liquid is placed onto a COVID-19 rapid antigen diagnostic test device. COVID-19 rapid testing in Rwanda. An antigen is the part of a pathogen that elicits an immune response. Antigen tests look for antigen proteins from the viral surface.
The safety results in the EoE KIDS study were generally consistent with the known safety profile of Dupixent in adolescents and adults with EoE. AEs more commonly observed with Dupixent (≥10%) in either weight-based dosing regimen compared to placebo during Part A were COVID-19, nausea, injection site pain and headache.
Molnupiravir. Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [7] It is taken by mouth. [7] Molnupiravir is a prodrug of the synthetic nucleoside derivative N4 -hydroxy cytidine and exerts its ...
AEs more commonly observed with Dupixent (≥5%) compared to placebo included injection site reactions (12% vs. 4%), accidental overdose (7% vs. 3%) and COVID-19 infection (8% vs. 5%). Detailed results from this trial will be provided to the U.S. Food and Drug Administration by year-end 2024 in response to the additional data requested for ...
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a ...
The approval is based on results from the landmark Phase 3 BOREAS and NOTUS trials, which were separately published in the New England Journal of Medicine and evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). All patients were on ...